利用登记处改善癌症治疗：接受白细胞介素-2 (IL-2) 治疗的患者的国家数据库。
The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).
机构信息
Department of Surgery, Rutgers Cancer Center Institute of New Jersey, 195 Little Albany Street, Room 2007, New Brunswick, NJ 08901, USA.
Department of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 3455, Los Angeles, CA 90033, USA.
出版信息
J Pers Med. 2014 Mar 7;4(1):52-64. doi: 10.3390/jpm4010052.
Registries evaluating un-randomized patients have provided valuable information with respect to a therapy's utility, treatment practices, and evolution over time. While immunotherapy for cancer has been around for more than three decades, data collection in the form of a registry has not been undertaken. The authors believe that establishing a registry to study HD IL-2 immunotherapy, which has been the only systemic therapy producing long term unmaintained remissions for advanced kidney cancer and melanoma for over 20 years, will be an important resource in understanding the impact of immunotherapy with HD IL-2 in a rapidly changing therapeutic environment. Optimizing administration and improving selection of appropriate patients likely to benefit from HD IL-2 immunotherapy are two of many benefits to be derived from this endeavor.
评估非随机患者的注册研究为一种疗法的实用性、治疗实践以及随着时间的推移而演变提供了有价值的信息。虽然癌症的免疫疗法已经存在了三十多年，但尚未以注册研究的形式进行数据收集。作者认为，建立一个注册研究来研究 HD IL-2 免疫疗法将是一个重要的资源，有助于了解在快速变化的治疗环境中 HD IL-2 免疫疗法的影响。优化 HD IL-2 免疫疗法的管理和改善选择可能从中受益的合适患者是这项努力的众多好处之一。
Zotero 插件